BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...Celgene Corp. (NASDAQ:CELG) to develop antibodies for inflammatory diseases; the most advanced is PD-1 agonist CC-90006...
BioCentury | Jun 21, 2019
Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

...ANB030 inhibited tetanus toxoid recall responses in human blood. AnaptysBio is also co-developing PD-1 agonist CC-90006...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

...development of Phase II idiopathic pulmonary fibrosis (IPF) therapy CC-90001 and Phase I autoimmune candidate CC-90006...
BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

...Intelligence Company Product Indication Checkpoint target Description Status AnaptysBio Inc. (NASDAQ:ANAB) / Celgene Corp. (NASDAQ:CELG) CC-90006...
Items per page:
1 - 4 of 4